Cerity Partners’s Corcept Therapeutics CORT Stock Holding History

Cerity Partners’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$69.3M	Buy	797,119 +65,430	+9%	+$3.95M	0.08%	201
2026 Q1	$29.5M	Sell	731,689 -23,606	-3%	-$883K	0.04%	343
2025 Q4	$26.3M	Sell	755,295 -3,131	-0.4%	-$246K	0.04%	357
2025 Q3	$63M	Buy	758,426 +11,833	+2%	+$856K	0.1%	179
2025 Q2	$54.8M	Buy	746,593 +131,799	+21%	+$9.56M	0.1%	185
2025 Q1	$70.2M	Buy	614,794 +6,848	+1%	+$417K	0.14%	148
2024 Q4	$30.6M	Sell	607,946 -3,838	-0.6%	-$201K	0.07%	240
2024 Q3	$28.3M	Sell	611,784 -63,770	-9%	-$2.27M	0.06%	257
2024 Q2	$21.9M	Sell	675,554 -289	-0%	-$7.92K	0.06%	263
2024 Q1	$17M	Buy	675,843 +601,776	+812%	+$14.2M	0.05%	330
2023 Q4	$2.41M	Sell	74,067 -436,175	-85%	-$12M	0.01%	715
2023 Q3	$13.9M	Buy	+510,242	New	+$14.8M	0.07%	246

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cerity Partners's CORT Position: Q2 2026 in Review

Cerity Partners increased its Corcept Therapeutics (CORT) stake by 8.9% in Q2 2026, buying an estimated $3.95M and bringing the position to 797,119 shares worth $69.3M. The position accounts for 0.08% of the portfolio, ranked #201.

Cerity Partners first reported a position in CORT in Q3 2023 and has held it in 12 quarters since. The position peaked at $70.2M in Q1 2025. 377 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Cerity Partners held 797,119 shares of Corcept Therapeutics worth $69.3M as of Q2 2026.
Cerity Partners bought 65,430 Corcept Therapeutics shares in Q2 2026, an estimated $3.95M.
Corcept Therapeutics made up 0.08% of Cerity Partners's portfolio in Q2 2026, its #201 holding.
Cerity Partners first reported a position in Corcept Therapeutics in Q3 2023 and has held it in 12 quarters since.
Cerity Partners's Corcept Therapeutics position peaked at $70.2M in Q1 2025.
377 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.